IgG4-related disease: 2026 so far

Phase 3 results moved from early hints to clearer flare reduction signals.

In the months covered, two phase 3 sources added higher-quality evidence that antibody-based strategies can reduce flares. A subgroup analysis reported fewer adjudicated flares (flares confirmed by a formal review process) with inebilizumab versus placebo. A full phase 3 trial reported that weekly obexelimab delayed the first flare and reduced steroid rescue over 52 weeks. Real-world comparisons and earlier reports continued to describe rituximab use for relapse control and steroid-sparing, including maintenance approaches and case-based long remissions, but with infections and other risks reported in some settings. This points to more targeted antibody options being tested for flare prevention, while the expected benefits and risks still depend on the specific drug and how strong the supporting evidence is.

Research covered in: January 2026, March 2026, June 2026, September 2026

Targeted oral and alternative immunosuppressants entered clinical reports.

So far in 2026, steroid-sparing approaches expanded beyond classic steroid induction plus add-on immunosuppression. An open-label phase 2a trial (a mid-stage study where everyone knows what treatment they get) reported many participants finishing rilzabrutinib treatment flare-free and off steroids and other immunosuppressants after a short taper. Serious adverse events occurred in 2 participants (including 1 death judged unrelated), and diarrhea was commonly reported. Smaller observational reports added additional early signals for other non-steroid options (e.g., azathioprine maintenance durability in a 10-person series; tofacitinib responses in a 7-person recurrent-disease series with a mild shingles case), while a blinded randomized trial (a study where assignment is by chance and masked) testing add-on mycophenolate mofetil for IgG4 re-rise without symptoms completed recruitment but has not reported outcomes. This means more steroid-sparing approaches are being explored, but much of the non-phase 3 evidence is still small or uncontrolled, and safety monitoring remains part of the tradeoff.

Research covered in: February 2026, July 2026, September 2026

Relapse management shifted toward post-relapse escalation and timing signals.

In the months covered, several cohorts reinforced that relapse is frequent and not random. Higher risk was linked to multi-organ disease and to specific lab patterns over time (e.g., IgG not normalizing within 12 months in one cohort; IgG4 change-over-time measures outperforming a single IgG4 value in another). Newer relapse-management evidence added a practical post-relapse signal: in a prospective cohort after a first relapse, intensifying both steroids and immunosuppressants was linked to fewer repeat relapses than intensifying immunosuppressants alone, especially with internal organ involvement. In organ-specific management, a small retrospective study in retroperitoneal fibrosis (inflammation and scarring behind the abdomen) suggested earlier steroid start after imaging diagnosis was linked to later ureter stent removal, and a small series reported pericardiectomy (surgery to remove the heart sac) improved constrictive pericarditis (a stiff heart covering that limits filling) when medical therapy failed. Taken together, the available reports frame relapse care more around individual risk, timing, and organ-specific complications than around a single one-size approach.

Research covered in: January 2026, February 2026, May 2026, July 2026, August 2026

Single lab values gave way to trend- and imaging-based signals.

New monitoring work in the months covered repeatedly separated one-time lab values from change-over-time signals. One cohort reported that a single IgG4 level did not predict relapse, while an IgG4-Ratio (trend measure) did. Another cohort linked a falling IgG4-to-total IgG ratio over time with better rituximab response. Additional candidate activity markers appeared, including CCL19 (an immune signaling protein) rising with active disease and falling with remission (and rising again with relapse), and a breath test (exhaled nitric oxide, a marker of airway inflammation) correlating with activity and lung involvement in untreated patients. Imaging-based monitoring also advanced: FDG-PET/CT (a scan that highlights metabolically active inflammation) was often diagnostically helpful in a tertiary cohort, and FAPI-PET/CT (a PET scan targeting activated fibroblasts) measures (including lesion burden and uptake) were linked to shorter relapse-free survival in one prospective study, with organ-to-organ uptake differences reported. This supports a shift toward combining lab trends, imaging, and newer biomarkers, while most markers still need broader validation across organs and care settings before they can reliably guide follow-up everywhere.

Research covered in: February 2026, March 2026, May 2026, August 2026, September 2026

More tools were proposed, but tissue confirmation stayed central.

Across January 2026 to September 2026 reports, the most consistent diagnostic pattern was that imaging and blood IgG4 alone could mimic cancer, lymphoma, infection, or other inflammatory diseases. Biopsy (sometimes repeat or larger sampling) was often decisive. Larger or structured diagnostic contributions included validation of updated bile-duct criteria with high specificity for key cancers in one dataset, a classification-performance study showing sensitivity improved when cardiovascular/retroperitoneal biopsy was available, and a pathology scoring approach using multiple tissue features to separate IgG4-RD from look-alikes within one dataset. Multiple case reports also showed the reverse pitfall -- true cancers or lymphomas occurring alongside IgG4-RD-like findings -- reinforcing why tissue interpretation and context matter. In difficult situations, especially when a mass is present, the evidence in these months supports combining imaging, labs, and adequate tissue review to reach the most reliable diagnosis.

Research covered in: January 2026, February 2026, March 2026, April 2026, May 2026, June 2026, July 2026, August 2026, September 2026